Pleural Effusion lecture

B
•Pleural effusion
syndrome
Learning objects
1. Definition of Pleural Effusion, normal pleural fluid composition
2. Pathology and Etiology of Pleural Effusion
3. Symptoms and physical findings in patients with pleural effusion
4. Imaging and Investigations in patients with pleural effusion
5. Parapneumonic effusion and empyema:features and management
6. Tuberculous pleural effusion
7. Malignant pleural effusion: features and management
Learning objects
1. Definition of Pleural Effusion, normal
pleural fluid composition
A pleural effusion is an accumulation of abnormal volumes
(>10–20mL) of fluid in the pleural space.
• The normal pleural space contains approximately 1-2 mL of fluid,
representing the balance between
• (1) hydrostatic and oncotic forces in the visceral and parietal pleural
vessels
• (2) extensive lymphatic drainage.
• Pleural effusions result from disruption of this balance.
• Pleural effusion is an indicator of an underlying disease process that
may be pulmonary or nonpulmonary in origin and may be acute or
chronic.
Normal pleural fluid has the following
characteristics:
 Clear ultrafiltrate of plasma that originates from the parietal pleura
 pH: 7.60-7.64
 Protein: < 2% (1-2 g/dL)
 White blood cells (WBC): < 1000/mm³
 RBC count < 5,000 cells/mm³
 Glucose: similar to that of plasma
 LDH: <50% plasma concentration
 Amylase: 30-110 U/L
 Triglycerides: <2 mmol/L
 Cholesterol: 3.5–6.5 mmol/L
2. Pathophysiology and Etiology of Pleural Effusion
Transudative Exudative
Pathophysiology •↑ Capillary hydrostatic pressure
(increased capillary wedge pressure)
•↓ Capillary oncotic pressure
•↑ Capillary permeability (e.g., due to
inflammation)
Common causes of
pleural effusion •Congestive heart failure
•Hepatic cirrhosis
•Nephrotic syndrome
•Protein-losing enteropathy
•Chronic kidney disease (Na+
retention)
•Infection
o Pneumonia (parapneumonic effusion)
o Tuberculosis
o Pleural empyema
o Parasitic illness
•Malignancies
•Trauma (high vascular permeability)
•Chylothorax
•Pseudochylothorax
Pleural Effusion lecture
• Depending on the overall protein concentration of the pleural effusion, a distinction is
made between transudate (< 30 g/L) and exudate (> 30 g/L).
• Transudate is a clear fluid containing few cells. It can emerge, e.g., as a consequence of
stasis: due to the increased hydrostatic pressure, the fluid efflux from the capillaries
increases. Or the colloid osmotic pressure in the vessels may be decreased (e.g., in the
event of hypoalbuminemia), causing more fluid to leak.
• Transudative effusion is caused by systemic factors: either increased hydrostatic
pressure (e.g.,CHF) or decreased oncotic pressure (e.g., nephrotic syndrome or cirrhosis).
Because these diseases are systemic, they usually cause bilateral and equal effusion.
• A transudative effusion needs no further evaluation. It resolves by adequate treatment
of the primary disease.
• Exudate, on the other hand, is rich in cells and is mostly a consequence of inflammation
or tumor diseases. Here, the permeability of the capillary walls for tumor cells, plasma
proteins, and other blood components increases (barrier dysfunction). These particles
will then form part of the pleural effusion, which is why exudate has such high content of
cells and proteins.
• Exudative effusion is caused by local processes: pneumonia, cancer, and tuberculosis.
• An exudative effusion will cause unilateral effusions. This type of effusion needs further
investigation
• In both cases, an increase in lymph production can also be observed. This increased
production then exceeds the maximum reabsorption capacity of the pleura and, thus,
also contributes to the increased fluid accumulation.
Study aid for the differentiating criteria of both forms
of pleural effusion
Overall protein
concentration
LDH
Transudate < 30 g/L < 200 U/L
Exudate > 30 g/L > 200 U/L
.
Light's
Criteria
Pleural fluid protein:serum
protein ratio
Transudat Exudat
 ≤ 0.5  > 0.5
Pleural
fluid LDH:serum LDH ratio
 ≤ 0.6  > 0.6
Pleural fluid LDH
 < ⅔ the upper
limit of normal
serum LDH
 > ⅔ the upper
limit of normal
serum LDH
• Pleural fluid LDH
• Levels > 1000 IU/L are suggestive of empyema, malignancy or rheumatoid effusion.
• Glucose
• A low pleural fluid glucose level (<3.4 mmol/l) may be found in empyema,
rheumatoid pleuritis and pleural effusions associated with TB, malignancy and
oesophageal rupture.
• A very low pleural glucose concentration (<1.6 mmol/l) is indicative of empyema
and rheumatoid disease.
• Pleural pH
• A pleural fluid pH of < 7.3 is associated with the same pathologies that cause a low
pleural fluid glucose.
• In malignant effusions, a pleural fluid pH of < 7.3 has been associated with more
extensive pleural involvement and shorter life expectancies.
• Amylase
• Pleural fluid amylase levels > 110U/L are indicative of pancreatitis, malignancy or a
ruptured oesophagus.
Special forms of pleural effusion
• Special forms of pleural effusion are the chylothorax and the hematothorax.
• Chylothorax consists primarily of lymphatic fluid; the pleural effusion is milky and
cloudy with a markedly elevated triglyceride content (> 110 mg/dL or 1.24 mmol/L),
cholesterol concentrations 200 mg/dL (5.18 mmol/L).
• Pseudochylothorax is mainly composed of cholesterol and commonly develops
from cell debris present in the pleural fluid for a long period of time. Cholesterol
concentrations >200 mg/dL (5.18 mmol/L), triglyceride concentrations <50 mg/dL
(0.56 mmol).
• A hematothorax is basically an accumulation of blood.
• Note: A bloody pleural effusion has to be considered suspicious for a tumor until
proven otherwise.
3. Symptoms and physical findings in
patients with pleural effusion
• Dyspnea or breathlessness is the cardinal symptom of
pleural effusion
• Besides symptoms that are due to accompanying or underlying
diseases, dyspnea is the only direct symptom. This shortness
of breath can be more or less pronounced, depending on the
severity of the effusion.
• Other symptoms include dry cough, pleuritic chest pain (suggesting
pleural inflammation), chest ‘heaviness’, and sometimes pain referred
to the shoulder or abdomen
Signs on clinical examination
• Signs on examination include:
• Visually: reduced chest expansion
(an asymmetrical chest expansion)
• Palpation: reduced tactile vocal fremitus
(vibration is being reflected at the line between lung tissue and pleural
effusion (2 matters of different density) and is, thus, not conducted to the
hand of the examiner)
• Auscultation: decreased or inaudible breath sounds over the effusion,
sometimes a patch of bronchial breathing above the fluid level
(because the lung is consolidated, i.e. compressed, here), a friction rub may
be heard with pleural inflammation.
• Percussion: a stony dull sound
(In the case of an effusion > 300 mL) on subscapular line or posterior axial
line. The upper border of this dullness follows a laterally ascending curve
(Ellis-Damoiseau line).
4. Imaging and Investigations in patients
with pleural effusion
• Ultrasonography (US)
• The most sensitive and gentle way to confirm a pleural effusion
diagnosis while the patient is sitting down. This way, effusions
with a volume of 20 mL or more will be depicted as
an anechoic (= dark) area. Sonographic imaging also allows
for the assessment of the pleura (fibrosis? tumor?) and the
organization of the effusion, as well as for identifying a suitable
site for puncture.
Ultrasonography (US)
CXR – chest X ray
• If the torso is erected, the effusion follows gravity and accumulates on
the costophrenic angles of the pleural spaces (costodiaphragmatic
recess).
• Sequential blunting of posterior, lateral, and then anterior
costophrenic angles are seen on radiographs as effusions increase in
size
• PA CXR will usually detect effusion volumes of 200mL or more;
• lateral CXR is more sensitive and may detect as little as 50mL pleural
fluid
• In X-ray images, the effusion is depicted as a homogenous shadow,
but on film you will see whiteness – opacity.
Erect posterior-anterior (PA)
projection
Classical CXR appearance is
of basal opacity obscuring
hemidiaphragm, with
concave upper border.
We say “ blunting costophrenic
angles ”
or “blunting costophrenic
sinuses”
• free-flowing effusions lying in a subpulmonic location (<75 mL) not
visible on Chest X Ray.
• Pleural effusions >75 mL of volume can be appreciated on lateral
chest radiography as blunting of costophrenic angle
• >175 mL of fluid can be appreciated on anterior-posterior chest
radiography
• 500 mL of fluid demonstrate a meniscus sign. Occasionally, the entire
hemithorax may be occupied by an effusion with associated
underlying lung collapse.
Erect (lateral projection)
Lateral decubitus position
the patient is laying either left lateral or right lateral on a trolley on top of a radiolucent
sponge
Note: when investigating pneumothorax, the side of interest should be up; when
investigating pleural effusions, the side of interest should be down
Thoracic computed tomography (CT)
scans
• will typically be
performed as part of
advanced diagnostic
procedures when the
etiology is unclear. It
allows for the detection
of the smallest amounts
of effusion, which will be
notable as sickle-shaped
consolidations between
the lung and thoracic
wall.
Pleural Effusion lecture
Investigations
 Thoracentesis. Thoracentesis is a procedure to remove extra fluid from the pleural cavity
between the lung and the chest wall using a needle. Removal of the fluid may help to relieve
severe symptoms for a short time. A few days after the extra fluid is removed, it is likely it will
begin to come back. The risk of a thoracentesis includes bleeding, infection, collapsed lung,
fluid in the lungs, and a sudden drop in blood pressure.
 Indwelling pleural catheter (IPC). An indwelling pleural catheter (IPC) is a small tube that is
inserted and left in place to keep fluid from building up around the lungs. One end of the tube
stays inside the chest and the other passes outside the body to allow fluid to drain. This type
of catheter may be used for long-term care so that a separate procedure won't need to be
done each time draining is needed. Risks of IPCs include infection and blockage of the
catheter.
 Pleurodesis. This is a procedure to close the pleural space so that fluid cannot collect there.
Fluid is first removed by thoracentesis, using a chest tube. A drug that causes the pleural
space to close is then inserted into the space through a chest tube. Drugs such
as bleomycin or talc may be used.
 Surgery. Surgery may be done to put in a shunt (tube) to carry the fluid from the pleural
cavity to the abdominal cavity, where the fluid is easier to remove. Pleurectomy is another
type of surgery that may be used. In this procedure, the part of the pleura that lines the chest
cavity is removed.
Thoracentesis or Pleural puncture
• This applies in particular to any case of a first or etiologically unclear pleural effusion.
• Purposes: differential diagnosis, obtaining testing material
• For this procedure, the patient is sitting down, a local anesthetic is applied, and the puncture needle is inserted
dorsally into the area of the effusion, but not below the 9th rib (to avoid sub-diaphragmatic injuries).
• In cases of small effusion, encapsulated effusions or atypical localizations, the finding of the puncture site should be
assisted sonographically.
• The material obtained from the puncture should be stored in 4 tubes:
• The first tube is for microbiology. From this material, a bacterial culture is made in order to perform a Gram
stain and, in case of suspected tuberculosis, a Ziehl-Neelsen stain. This tube has to be kept sterile at all times!
• The second tube is for clinical chemistry. With this material, various parameters will be determined: cell count (e.g.,
lymphocytosis for cases of tuberculosis and sarcoidosis), pH level, glucose (diminished glucose levels and an acidic
pH suggest an inflammatory or malignant genesis), triglyceride (elevated in case of a
chylothorax), amylase and lipase (elevated in case of a pancreatic effusion caused by
pancreatitis, pancreas carcinoma, or others), and specific tumor markers in case of a suspected tumor disease.
• The third tube is for pathology. Here, a cytological smear is prepared for the evaluation of malignancy. Indications
for malignancy would include, inter alia, a shift in the nucleus-plasma relation, many mitoses, and multinucleated
cells.
• A fourth tube is kept for other, not yet foreseeable examinations
Macroscopically, a first assessment of the punctured effusion can be made:
Serous Bright, clear, ‘amber’ fluid: mostly transudate with few cells
Hemorrhagic Reddish: bloody transudate or exudate – trauma or malignoma?
Chylous Milky and cloudy: chylothorax
Purulent Yellowish and dull: exudate in cases of pleural empyema, tuberculosis,
or abscesses
• Note:
• Every pleural puncture should be followed by a chest X-ray to
exclude an iatrogenic pneumothorax!
• never extract more than 1.5 L in a single session since there is the
risk of re-expansion edema or great losses of protein. Therefore, for
larger effusions, treatment consists of suction drainage over the
course of several days.
Parapneumonic effusion and
empyema: definition and clinical features
• simple parapneumonic effusion occur in up to 57% of patients with
pneumonia.
• in some cases, progress to a complicated parapneumonic effusion and
eventually empyema
• Pleural infection may also occur in the absence of a preceding
pneumonic illness
Simple
parapneumonic
eusion
Exudative stage
Clear sterile fluid with normal pH, glucose, LDH
Frequently resolves with antibiotics alone
Drainage not usually required
Complicated
parapneumonic e-
usion
Fibrinopurulent stage
Fibrin deposited and septations occur
Fluid infected but not yet purulent; appears clear or
cloudy/turbid
H <7.20, glucose <2.2 mmol/L (<40 mg/dL) and LDH >1000 IU/L.
Gram stain/culture may be positive
Drainage required
Empyema Pus in pleural space
May be free-owing or multiloculated Gram stain/culture may be positive Drainage required
Eventually, fibroblastes growth may result in development of thick pleural peel (organizing
stage). Treatment at this stage is difficult and decortication may be required
Typical findings: colour depends on pathogen, viscous because of high concentration of WBC
and fibrin. pH <7.2, glucose <2.2mmol/L, and LDH >1,000IU/L. WBC > 10,000/mm3.
Parapneumonic effusion and
empyema: Clinical features
• Common
• Similar to clinical presentation of pneumonia: fever, sputum production,
chest pain, breathlessness
• cases of ‘slow-to-respond’ pneumonia (e.g. failure of CRP to fall ≥50% in
first 3 days)
• pleural effusion with fever
• or high-risk groups (diabetes, IVDU, and chronic alcohol use) with non-
specific symptoms such as weight loss, atypical chest pain, vomiting, or
oesophageal instrumentation
• Anaerobic empyema may present less acutely, often with weight loss and
without fever.
• Empyema may rarely occur following bronchial obstruction from a tumor
or foreign body.
Parapneumonic effusion and
empyema: bacteriology
• Community-acquired infection (% of cases):
• Streptococcus ‘milleri’ group (30%)
• Anaerobes (15–30%)
• Streptococcus pneumoniae (15%)
• Staphylococcus aureus (10%)
• Other less common organisms include other streptococci,
enterobacteriaceae, H. influenzae, Pseudomonas, TB, and Nocardia
Hospital-acquired infection (% of cases):
• MRSA (25–30%)
• Staphylococcus aureus (10–20%) • Enterobacteriaceae (20%) •
Enterococci (10%) • Others include streptococci, Pseudomonas, and
anaerobes.
Pleural infection is frequently polymicrobial.
Parapneumonic effusion and
empyema: management
• Antibiotics
• All patients with parapneumonic pleural infection should be treated with
antibiotics; refer to local hospital prescribing guidelines. Typical choices:
• Community-acquired empyema—β-lactam/β-lactamase inhibitor (e.g.
• co-amoxiclav) or second-generation cephalosporin (e.g. cefuroxime),
• combined with metronidazole for anaerobic cover. Ciprofloxacin and
clindamycin together may be appropriate
• Hospital-acquired empyema—cover Gram-positive and Gram-negative
organisms and anaerobes. MRSA infection is common. Consult with
microbiology team. One option is meropenem and vancomycin.
Chest tube drainage
• Indications for chest tube
drainage
• Purulent pleural fluid
• Organisms on pleural fluid Gram
stain or culture
• Pleural fluid pH <7.2.
Intrapleural fibrinolytics
• combination of intrapleural
alteplase (tPA) and dornase alfa
(DNase) significantly improved
CXR appearances for patients
with pleural infection
6. Tuberculous pleural effusion
• develops from a delayed hypersensitivity reaction to mycobacteria released
into the pleural space. It is a common manifestation of TB in regions
with a high prevalence, affecting children and young adults; it may also be
associated with reactivation of TB in older individuals.
• Clinical features
• fever, sweating, weight loss, and dyspnoea, although it may present acutely
with pleuritic chest pain and fever, mimicking pneumonia
• Pleural fluid composition:
• Lymphocytosis, exudative effusion, pH and glucose moderately depressed,
mesothelial cells rare. Pleural fluid cultures are positive in 25% of cases and
take 2–6 weeks
7. Malignant pleural effusion: causes and
investigations
• Commonest cause of exudative pleural effusion in patients older than 60y.o.
• Causes: Most malignant effusions are metastatic, with lung and breast the most
common
• Clinical features: Breathlessness is the main symptom; chest pain, cough, weight
loss, and anorexia may also be present.
• A small proportion of patients are asymptomatic. Effusions may be unilateral or
bilateral and are frequently large volume
• Key investigations in patients suspected to have a malignant effusion are:
• Pleural fluid cytology
• CT chest with pleural contrast
• Pleural biopsy histology
• Serum/pleural fluid tumour markers
Malignant pleural effusion: management
• Observation and follow-up if asymptomatic.
• Therapeutic pleural aspiration of 1–1.5L pleural fluid to improve
breathlessness. Can be performed at the bedside as a day-case
procedure, avoiding hospital admission.
• Intercostal chest drainage and pleurodesis
• Insertion of a long-term IPC
Pleural Effusion lecture
Thank you for
Attention!
1 sur 36

Recommandé

Pleural Effusion for Undergraduates par
Pleural Effusion for UndergraduatesPleural Effusion for Undergraduates
Pleural Effusion for UndergraduatesSesha Sai
13.4K vues52 diapositives
Pleural effusion par
Pleural effusion Pleural effusion
Pleural effusion Ujaas Dawar
1.6K vues76 diapositives
Pleural effusion par
Pleural effusionPleural effusion
Pleural effusionEyad Miskawi
12.2K vues38 diapositives
Pleural Effusiion par
Pleural EffusiionPleural Effusiion
Pleural EffusiionHaiderAlkhafaji5
134 vues37 diapositives
Pleural effusion.pptx cme march par
Pleural effusion.pptx cme marchPleural effusion.pptx cme march
Pleural effusion.pptx cme marchRISHIKESAN K V
15.4K vues72 diapositives
Pleuresy par
PleuresyPleuresy
Pleuresyaiyub medicine
7.4K vues83 diapositives

Contenu connexe

Similaire à Pleural Effusion lecture

pleuraleffusion.pptx par
pleuraleffusion.pptxpleuraleffusion.pptx
pleuraleffusion.pptxThenarasanG
26 vues47 diapositives
Pleural effusion par
Pleural effusionPleural effusion
Pleural effusionAaron Mascarenhas
18.7K vues33 diapositives
Approach to pleural effusion par
Approach to pleural effusionApproach to pleural effusion
Approach to pleural effusionMuhammad Asim Rana
57.7K vues91 diapositives
Pleural effusion par
Pleural effusion Pleural effusion
Pleural effusion HAMAD DHUHAYR
9.4K vues21 diapositives
L5 pleural effusion par
L5 pleural effusionL5 pleural effusion
L5 pleural effusionbilal natiq
1.3K vues41 diapositives
Pleural effusion ppt par
Pleural effusion pptPleural effusion ppt
Pleural effusion pptMosese HULKSTAH Tuapati JNR
1.4K vues20 diapositives

Similaire à Pleural Effusion lecture(20)

L5 pleural effusion par bilal natiq
L5 pleural effusionL5 pleural effusion
L5 pleural effusion
bilal natiq1.3K vues
approachtopleuraleffusion-140205151929-phpapp01.pdf par NellyPhiri5
approachtopleuraleffusion-140205151929-phpapp01.pdfapproachtopleuraleffusion-140205151929-phpapp01.pdf
approachtopleuraleffusion-140205151929-phpapp01.pdf
NellyPhiri57 vues
Malignant Pleural Effusion.pptx par YY19921
Malignant Pleural Effusion.pptxMalignant Pleural Effusion.pptx
Malignant Pleural Effusion.pptx
YY199212 vues
Pleural Fluid and Analysis of blood.pptx par Anonymous210580
Pleural Fluid and Analysis of blood.pptxPleural Fluid and Analysis of blood.pptx
Pleural Fluid and Analysis of blood.pptx
Anonymous21058015 vues
6.Pleural Effusions par ghalan
6.Pleural Effusions6.Pleural Effusions
6.Pleural Effusions
ghalan5.7K vues
PLEURAL EFFUSION BY Mr. AKRAM KHAN par Akram Khan
PLEURAL EFFUSION BY Mr. AKRAM KHANPLEURAL EFFUSION BY Mr. AKRAM KHAN
PLEURAL EFFUSION BY Mr. AKRAM KHAN
Akram Khan497 vues
4 pleural effusions par internalmed
4 pleural effusions4 pleural effusions
4 pleural effusions
internalmed2.1K vues

Dernier

NMP-9.pptx par
NMP-9.pptxNMP-9.pptx
NMP-9.pptxSai Sailesh Kumar Goothy
15 vues46 diapositives
BUKTI SOSIALISASI KODE ETIK DAN PERATURAN INTERNAL.docx 4,2,C.docx par
BUKTI SOSIALISASI KODE ETIK DAN PERATURAN INTERNAL.docx 4,2,C.docxBUKTI SOSIALISASI KODE ETIK DAN PERATURAN INTERNAL.docx 4,2,C.docx
BUKTI SOSIALISASI KODE ETIK DAN PERATURAN INTERNAL.docx 4,2,C.docxInkhaRina
32 vues4 diapositives
LMLR 2023 Back and Joint Pain at 50 par
LMLR 2023 Back and Joint Pain at 50LMLR 2023 Back and Joint Pain at 50
LMLR 2023 Back and Joint Pain at 50Allan Corpuz
324 vues77 diapositives
Top PCD Pharma Franchise Companies in India | Saphnix Lifesciences par
Top PCD Pharma Franchise Companies in India | Saphnix LifesciencesTop PCD Pharma Franchise Companies in India | Saphnix Lifesciences
Top PCD Pharma Franchise Companies in India | Saphnix LifesciencesSaphnix Lifesciences
25 vues11 diapositives
eTEP -RS Dr.TVR.pptx par
eTEP -RS Dr.TVR.pptxeTEP -RS Dr.TVR.pptx
eTEP -RS Dr.TVR.pptxVarunraju9
131 vues33 diapositives
treatment of oropharyngeal cancer.pptx par
treatment of oropharyngeal cancer.pptxtreatment of oropharyngeal cancer.pptx
treatment of oropharyngeal cancer.pptxWoldemariam Beka
9 vues53 diapositives

Dernier(20)

BUKTI SOSIALISASI KODE ETIK DAN PERATURAN INTERNAL.docx 4,2,C.docx par InkhaRina
BUKTI SOSIALISASI KODE ETIK DAN PERATURAN INTERNAL.docx 4,2,C.docxBUKTI SOSIALISASI KODE ETIK DAN PERATURAN INTERNAL.docx 4,2,C.docx
BUKTI SOSIALISASI KODE ETIK DAN PERATURAN INTERNAL.docx 4,2,C.docx
InkhaRina32 vues
LMLR 2023 Back and Joint Pain at 50 par Allan Corpuz
LMLR 2023 Back and Joint Pain at 50LMLR 2023 Back and Joint Pain at 50
LMLR 2023 Back and Joint Pain at 50
Allan Corpuz324 vues
Top PCD Pharma Franchise Companies in India | Saphnix Lifesciences par Saphnix Lifesciences
Top PCD Pharma Franchise Companies in India | Saphnix LifesciencesTop PCD Pharma Franchise Companies in India | Saphnix Lifesciences
Top PCD Pharma Franchise Companies in India | Saphnix Lifesciences
eTEP -RS Dr.TVR.pptx par Varunraju9
eTEP -RS Dr.TVR.pptxeTEP -RS Dr.TVR.pptx
eTEP -RS Dr.TVR.pptx
Varunraju9131 vues
Structural Racism and Public Health: How to Talk to Policymakers and Communit... par katiequigley33
Structural Racism and Public Health: How to Talk to Policymakers and Communit...Structural Racism and Public Health: How to Talk to Policymakers and Communit...
Structural Racism and Public Health: How to Talk to Policymakers and Communit...
katiequigley33627 vues
Cholera Romy W. (3).pptx par rweth613
Cholera Romy W. (3).pptxCholera Romy W. (3).pptx
Cholera Romy W. (3).pptx
rweth61338 vues
PATIENTCOUNSELLING in.pptx par skShashi1
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptx
skShashi116 vues
Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (... par PeerVoice
Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...
Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...
PeerVoice8 vues
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends par muskansbl01
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness TrendsTop Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
muskansbl0134 vues
The Art of naming drugs.pptx par DanaKarem1
The Art of naming drugs.pptxThe Art of naming drugs.pptx
The Art of naming drugs.pptx
DanaKarem19 vues
Top 10 Pharma Companies in Mumbai | Medibyte par Medibyte Pharma
Top 10 Pharma Companies in Mumbai | MedibyteTop 10 Pharma Companies in Mumbai | Medibyte
Top 10 Pharma Companies in Mumbai | Medibyte
Medibyte Pharma17 vues

Pleural Effusion lecture

  • 2. Learning objects 1. Definition of Pleural Effusion, normal pleural fluid composition 2. Pathology and Etiology of Pleural Effusion 3. Symptoms and physical findings in patients with pleural effusion 4. Imaging and Investigations in patients with pleural effusion 5. Parapneumonic effusion and empyema:features and management 6. Tuberculous pleural effusion 7. Malignant pleural effusion: features and management Learning objects
  • 3. 1. Definition of Pleural Effusion, normal pleural fluid composition A pleural effusion is an accumulation of abnormal volumes (>10–20mL) of fluid in the pleural space. • The normal pleural space contains approximately 1-2 mL of fluid, representing the balance between • (1) hydrostatic and oncotic forces in the visceral and parietal pleural vessels • (2) extensive lymphatic drainage. • Pleural effusions result from disruption of this balance. • Pleural effusion is an indicator of an underlying disease process that may be pulmonary or nonpulmonary in origin and may be acute or chronic.
  • 4. Normal pleural fluid has the following characteristics:  Clear ultrafiltrate of plasma that originates from the parietal pleura  pH: 7.60-7.64  Protein: < 2% (1-2 g/dL)  White blood cells (WBC): < 1000/mm³  RBC count < 5,000 cells/mm³  Glucose: similar to that of plasma  LDH: <50% plasma concentration  Amylase: 30-110 U/L  Triglycerides: <2 mmol/L  Cholesterol: 3.5–6.5 mmol/L
  • 5. 2. Pathophysiology and Etiology of Pleural Effusion Transudative Exudative Pathophysiology •↑ Capillary hydrostatic pressure (increased capillary wedge pressure) •↓ Capillary oncotic pressure •↑ Capillary permeability (e.g., due to inflammation) Common causes of pleural effusion •Congestive heart failure •Hepatic cirrhosis •Nephrotic syndrome •Protein-losing enteropathy •Chronic kidney disease (Na+ retention) •Infection o Pneumonia (parapneumonic effusion) o Tuberculosis o Pleural empyema o Parasitic illness •Malignancies •Trauma (high vascular permeability) •Chylothorax •Pseudochylothorax
  • 7. • Depending on the overall protein concentration of the pleural effusion, a distinction is made between transudate (< 30 g/L) and exudate (> 30 g/L). • Transudate is a clear fluid containing few cells. It can emerge, e.g., as a consequence of stasis: due to the increased hydrostatic pressure, the fluid efflux from the capillaries increases. Or the colloid osmotic pressure in the vessels may be decreased (e.g., in the event of hypoalbuminemia), causing more fluid to leak. • Transudative effusion is caused by systemic factors: either increased hydrostatic pressure (e.g.,CHF) or decreased oncotic pressure (e.g., nephrotic syndrome or cirrhosis). Because these diseases are systemic, they usually cause bilateral and equal effusion. • A transudative effusion needs no further evaluation. It resolves by adequate treatment of the primary disease. • Exudate, on the other hand, is rich in cells and is mostly a consequence of inflammation or tumor diseases. Here, the permeability of the capillary walls for tumor cells, plasma proteins, and other blood components increases (barrier dysfunction). These particles will then form part of the pleural effusion, which is why exudate has such high content of cells and proteins. • Exudative effusion is caused by local processes: pneumonia, cancer, and tuberculosis. • An exudative effusion will cause unilateral effusions. This type of effusion needs further investigation • In both cases, an increase in lymph production can also be observed. This increased production then exceeds the maximum reabsorption capacity of the pleura and, thus, also contributes to the increased fluid accumulation.
  • 8. Study aid for the differentiating criteria of both forms of pleural effusion Overall protein concentration LDH Transudate < 30 g/L < 200 U/L Exudate > 30 g/L > 200 U/L . Light's Criteria Pleural fluid protein:serum protein ratio Transudat Exudat  ≤ 0.5  > 0.5 Pleural fluid LDH:serum LDH ratio  ≤ 0.6  > 0.6 Pleural fluid LDH  < ⅔ the upper limit of normal serum LDH  > ⅔ the upper limit of normal serum LDH
  • 9. • Pleural fluid LDH • Levels > 1000 IU/L are suggestive of empyema, malignancy or rheumatoid effusion. • Glucose • A low pleural fluid glucose level (<3.4 mmol/l) may be found in empyema, rheumatoid pleuritis and pleural effusions associated with TB, malignancy and oesophageal rupture. • A very low pleural glucose concentration (<1.6 mmol/l) is indicative of empyema and rheumatoid disease. • Pleural pH • A pleural fluid pH of < 7.3 is associated with the same pathologies that cause a low pleural fluid glucose. • In malignant effusions, a pleural fluid pH of < 7.3 has been associated with more extensive pleural involvement and shorter life expectancies. • Amylase • Pleural fluid amylase levels > 110U/L are indicative of pancreatitis, malignancy or a ruptured oesophagus.
  • 10. Special forms of pleural effusion • Special forms of pleural effusion are the chylothorax and the hematothorax. • Chylothorax consists primarily of lymphatic fluid; the pleural effusion is milky and cloudy with a markedly elevated triglyceride content (> 110 mg/dL or 1.24 mmol/L), cholesterol concentrations 200 mg/dL (5.18 mmol/L). • Pseudochylothorax is mainly composed of cholesterol and commonly develops from cell debris present in the pleural fluid for a long period of time. Cholesterol concentrations >200 mg/dL (5.18 mmol/L), triglyceride concentrations <50 mg/dL (0.56 mmol). • A hematothorax is basically an accumulation of blood. • Note: A bloody pleural effusion has to be considered suspicious for a tumor until proven otherwise.
  • 11. 3. Symptoms and physical findings in patients with pleural effusion • Dyspnea or breathlessness is the cardinal symptom of pleural effusion • Besides symptoms that are due to accompanying or underlying diseases, dyspnea is the only direct symptom. This shortness of breath can be more or less pronounced, depending on the severity of the effusion. • Other symptoms include dry cough, pleuritic chest pain (suggesting pleural inflammation), chest ‘heaviness’, and sometimes pain referred to the shoulder or abdomen
  • 12. Signs on clinical examination • Signs on examination include: • Visually: reduced chest expansion (an asymmetrical chest expansion) • Palpation: reduced tactile vocal fremitus (vibration is being reflected at the line between lung tissue and pleural effusion (2 matters of different density) and is, thus, not conducted to the hand of the examiner) • Auscultation: decreased or inaudible breath sounds over the effusion, sometimes a patch of bronchial breathing above the fluid level (because the lung is consolidated, i.e. compressed, here), a friction rub may be heard with pleural inflammation. • Percussion: a stony dull sound (In the case of an effusion > 300 mL) on subscapular line or posterior axial line. The upper border of this dullness follows a laterally ascending curve (Ellis-Damoiseau line).
  • 13. 4. Imaging and Investigations in patients with pleural effusion • Ultrasonography (US) • The most sensitive and gentle way to confirm a pleural effusion diagnosis while the patient is sitting down. This way, effusions with a volume of 20 mL or more will be depicted as an anechoic (= dark) area. Sonographic imaging also allows for the assessment of the pleura (fibrosis? tumor?) and the organization of the effusion, as well as for identifying a suitable site for puncture.
  • 15. CXR – chest X ray • If the torso is erected, the effusion follows gravity and accumulates on the costophrenic angles of the pleural spaces (costodiaphragmatic recess). • Sequential blunting of posterior, lateral, and then anterior costophrenic angles are seen on radiographs as effusions increase in size • PA CXR will usually detect effusion volumes of 200mL or more; • lateral CXR is more sensitive and may detect as little as 50mL pleural fluid • In X-ray images, the effusion is depicted as a homogenous shadow, but on film you will see whiteness – opacity.
  • 16. Erect posterior-anterior (PA) projection Classical CXR appearance is of basal opacity obscuring hemidiaphragm, with concave upper border. We say “ blunting costophrenic angles ” or “blunting costophrenic sinuses”
  • 17. • free-flowing effusions lying in a subpulmonic location (<75 mL) not visible on Chest X Ray. • Pleural effusions >75 mL of volume can be appreciated on lateral chest radiography as blunting of costophrenic angle • >175 mL of fluid can be appreciated on anterior-posterior chest radiography • 500 mL of fluid demonstrate a meniscus sign. Occasionally, the entire hemithorax may be occupied by an effusion with associated underlying lung collapse.
  • 19. Lateral decubitus position the patient is laying either left lateral or right lateral on a trolley on top of a radiolucent sponge Note: when investigating pneumothorax, the side of interest should be up; when investigating pleural effusions, the side of interest should be down
  • 20. Thoracic computed tomography (CT) scans • will typically be performed as part of advanced diagnostic procedures when the etiology is unclear. It allows for the detection of the smallest amounts of effusion, which will be notable as sickle-shaped consolidations between the lung and thoracic wall.
  • 22. Investigations  Thoracentesis. Thoracentesis is a procedure to remove extra fluid from the pleural cavity between the lung and the chest wall using a needle. Removal of the fluid may help to relieve severe symptoms for a short time. A few days after the extra fluid is removed, it is likely it will begin to come back. The risk of a thoracentesis includes bleeding, infection, collapsed lung, fluid in the lungs, and a sudden drop in blood pressure.  Indwelling pleural catheter (IPC). An indwelling pleural catheter (IPC) is a small tube that is inserted and left in place to keep fluid from building up around the lungs. One end of the tube stays inside the chest and the other passes outside the body to allow fluid to drain. This type of catheter may be used for long-term care so that a separate procedure won't need to be done each time draining is needed. Risks of IPCs include infection and blockage of the catheter.  Pleurodesis. This is a procedure to close the pleural space so that fluid cannot collect there. Fluid is first removed by thoracentesis, using a chest tube. A drug that causes the pleural space to close is then inserted into the space through a chest tube. Drugs such as bleomycin or talc may be used.  Surgery. Surgery may be done to put in a shunt (tube) to carry the fluid from the pleural cavity to the abdominal cavity, where the fluid is easier to remove. Pleurectomy is another type of surgery that may be used. In this procedure, the part of the pleura that lines the chest cavity is removed.
  • 23. Thoracentesis or Pleural puncture • This applies in particular to any case of a first or etiologically unclear pleural effusion. • Purposes: differential diagnosis, obtaining testing material • For this procedure, the patient is sitting down, a local anesthetic is applied, and the puncture needle is inserted dorsally into the area of the effusion, but not below the 9th rib (to avoid sub-diaphragmatic injuries). • In cases of small effusion, encapsulated effusions or atypical localizations, the finding of the puncture site should be assisted sonographically. • The material obtained from the puncture should be stored in 4 tubes: • The first tube is for microbiology. From this material, a bacterial culture is made in order to perform a Gram stain and, in case of suspected tuberculosis, a Ziehl-Neelsen stain. This tube has to be kept sterile at all times! • The second tube is for clinical chemistry. With this material, various parameters will be determined: cell count (e.g., lymphocytosis for cases of tuberculosis and sarcoidosis), pH level, glucose (diminished glucose levels and an acidic pH suggest an inflammatory or malignant genesis), triglyceride (elevated in case of a chylothorax), amylase and lipase (elevated in case of a pancreatic effusion caused by pancreatitis, pancreas carcinoma, or others), and specific tumor markers in case of a suspected tumor disease. • The third tube is for pathology. Here, a cytological smear is prepared for the evaluation of malignancy. Indications for malignancy would include, inter alia, a shift in the nucleus-plasma relation, many mitoses, and multinucleated cells. • A fourth tube is kept for other, not yet foreseeable examinations
  • 24. Macroscopically, a first assessment of the punctured effusion can be made: Serous Bright, clear, ‘amber’ fluid: mostly transudate with few cells Hemorrhagic Reddish: bloody transudate or exudate – trauma or malignoma? Chylous Milky and cloudy: chylothorax Purulent Yellowish and dull: exudate in cases of pleural empyema, tuberculosis, or abscesses
  • 25. • Note: • Every pleural puncture should be followed by a chest X-ray to exclude an iatrogenic pneumothorax! • never extract more than 1.5 L in a single session since there is the risk of re-expansion edema or great losses of protein. Therefore, for larger effusions, treatment consists of suction drainage over the course of several days.
  • 26. Parapneumonic effusion and empyema: definition and clinical features • simple parapneumonic effusion occur in up to 57% of patients with pneumonia. • in some cases, progress to a complicated parapneumonic effusion and eventually empyema • Pleural infection may also occur in the absence of a preceding pneumonic illness
  • 27. Simple parapneumonic eusion Exudative stage Clear sterile fluid with normal pH, glucose, LDH Frequently resolves with antibiotics alone Drainage not usually required Complicated parapneumonic e- usion Fibrinopurulent stage Fibrin deposited and septations occur Fluid infected but not yet purulent; appears clear or cloudy/turbid H <7.20, glucose <2.2 mmol/L (<40 mg/dL) and LDH >1000 IU/L. Gram stain/culture may be positive Drainage required Empyema Pus in pleural space May be free-owing or multiloculated Gram stain/culture may be positive Drainage required Eventually, fibroblastes growth may result in development of thick pleural peel (organizing stage). Treatment at this stage is difficult and decortication may be required Typical findings: colour depends on pathogen, viscous because of high concentration of WBC and fibrin. pH <7.2, glucose <2.2mmol/L, and LDH >1,000IU/L. WBC > 10,000/mm3.
  • 28. Parapneumonic effusion and empyema: Clinical features • Common • Similar to clinical presentation of pneumonia: fever, sputum production, chest pain, breathlessness • cases of ‘slow-to-respond’ pneumonia (e.g. failure of CRP to fall ≥50% in first 3 days) • pleural effusion with fever • or high-risk groups (diabetes, IVDU, and chronic alcohol use) with non- specific symptoms such as weight loss, atypical chest pain, vomiting, or oesophageal instrumentation • Anaerobic empyema may present less acutely, often with weight loss and without fever. • Empyema may rarely occur following bronchial obstruction from a tumor or foreign body.
  • 29. Parapneumonic effusion and empyema: bacteriology • Community-acquired infection (% of cases): • Streptococcus ‘milleri’ group (30%) • Anaerobes (15–30%) • Streptococcus pneumoniae (15%) • Staphylococcus aureus (10%) • Other less common organisms include other streptococci, enterobacteriaceae, H. influenzae, Pseudomonas, TB, and Nocardia Hospital-acquired infection (% of cases): • MRSA (25–30%) • Staphylococcus aureus (10–20%) • Enterobacteriaceae (20%) • Enterococci (10%) • Others include streptococci, Pseudomonas, and anaerobes. Pleural infection is frequently polymicrobial.
  • 30. Parapneumonic effusion and empyema: management • Antibiotics • All patients with parapneumonic pleural infection should be treated with antibiotics; refer to local hospital prescribing guidelines. Typical choices: • Community-acquired empyema—β-lactam/β-lactamase inhibitor (e.g. • co-amoxiclav) or second-generation cephalosporin (e.g. cefuroxime), • combined with metronidazole for anaerobic cover. Ciprofloxacin and clindamycin together may be appropriate • Hospital-acquired empyema—cover Gram-positive and Gram-negative organisms and anaerobes. MRSA infection is common. Consult with microbiology team. One option is meropenem and vancomycin.
  • 31. Chest tube drainage • Indications for chest tube drainage • Purulent pleural fluid • Organisms on pleural fluid Gram stain or culture • Pleural fluid pH <7.2. Intrapleural fibrinolytics • combination of intrapleural alteplase (tPA) and dornase alfa (DNase) significantly improved CXR appearances for patients with pleural infection
  • 32. 6. Tuberculous pleural effusion • develops from a delayed hypersensitivity reaction to mycobacteria released into the pleural space. It is a common manifestation of TB in regions with a high prevalence, affecting children and young adults; it may also be associated with reactivation of TB in older individuals. • Clinical features • fever, sweating, weight loss, and dyspnoea, although it may present acutely with pleuritic chest pain and fever, mimicking pneumonia • Pleural fluid composition: • Lymphocytosis, exudative effusion, pH and glucose moderately depressed, mesothelial cells rare. Pleural fluid cultures are positive in 25% of cases and take 2–6 weeks
  • 33. 7. Malignant pleural effusion: causes and investigations • Commonest cause of exudative pleural effusion in patients older than 60y.o. • Causes: Most malignant effusions are metastatic, with lung and breast the most common • Clinical features: Breathlessness is the main symptom; chest pain, cough, weight loss, and anorexia may also be present. • A small proportion of patients are asymptomatic. Effusions may be unilateral or bilateral and are frequently large volume • Key investigations in patients suspected to have a malignant effusion are: • Pleural fluid cytology • CT chest with pleural contrast • Pleural biopsy histology • Serum/pleural fluid tumour markers
  • 34. Malignant pleural effusion: management • Observation and follow-up if asymptomatic. • Therapeutic pleural aspiration of 1–1.5L pleural fluid to improve breathlessness. Can be performed at the bedside as a day-case procedure, avoiding hospital admission. • Intercostal chest drainage and pleurodesis • Insertion of a long-term IPC